BioSpace News Archive

The notice concerns the following two transparency notifications:

Financial and operating highlights during the third quarter of fiscal 2018 include:

The company will use the funds, awarded through the National Institute of Allergy and Infectious Disease (NIAID), to continue development and optimization of its transchromosomal (Tc) goats to broaden the Tc animal platform developed by SAB Biotherapeutics, to small ungulate species.

For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion.

Edwards Lifesciences, today reported financial results for the quarter ended December 31, 2017.

Revance announced presentation of clinical data from the company’s two pivotal SAKURA Phase 3 trials of DaxibotulinumtoxinA Injectable (RT002) at the 20th annual IMCAS (International Master Course on Aging Skin) World Congress, taking place at Palais des Congrès, Paris, France, February 1-3, 2018.

Ironwood today announced it will host its fourth quarter and full-year 2017 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 15, 2018.

Anika Therapeutics today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to collaborate on research to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis (OA).

Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly & Company, ImClone Systems, Dendreon and Pfizer.

InflaRx N.V. will present data on IFX-1, an anti-C5a monoclonal antibody, at two international scientific conferences.